Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (490)	12/30/2018 4:10:59 PM
From: rkrw	2 Recommendations Recommended By ghmm keokalani'nui Read Replies (3) \| Respond to of 684

Top level screen would be sub cash, no debt, two or more years cash on hand. AGTC, CYCC, TRVN, JNCE, VICL, VBLT, NLNK, IMDZ, CYTR, CMRX, CBIO, NVIV, TENX, ARAV, MNLO, ACHN, ETTX, ADRO, SRRA, PTIE, PRTA, ZYNE, AKBA, CLBS, ADVM, MLND, SCPH, EDGE, PIRS, CALA. Looking back, using a cut of 12/31/07. Around an equal number of bankruptcies to takeovers. Some reverse merges. The biggest discounts to cash went bankrupt: AGIO (debt load), TPPH, OSCI (debt), PANC, CJC (debt). Biggest winner by far was INHX, bought by Bristol. $25m market cap, $56m cash, small burn rate. ANDS was another winner, HCV play, acquired by Merck. Of the smallest 35 market caps at that time, not counting reverse merges, quick glance, the only ones still around are PTN and TKM (ABUS).